Integrated Wellness · Research education
Compare the science.
Put two to four molecules side by side. Similar goals do not mean similar mechanisms, evidence or risks.
Choose your molecules
3 of 4 selected · Choose at least 2
Explore a comparison:
On smaller screens, scroll the table sideways to see each molecule.
| Research dimension | DSIP Limited / uncertain | Epitalon Preclinical | Selank Limited / uncertain |
|---|---|---|---|
| Biological classification | Delta sleep-inducing nonapeptide | Synthetic AEDG tetrapeptide | Synthetic tuftsin-related heptapeptide |
| Mechanism & pathway | Historical experiments explore sleep- and stress-related neuropeptide signaling. A single established receptor mechanism that explains reliable human sleep benefits has not been demonstrated. | Synthetic tetrapeptide investigated in Russian longevity research literature for pineal-telomerase signaling. | Research proposes effects on neuropeptide and inhibitory signaling, including GABA-related pathways. A definitive mechanism for broadly reproducible human clinical benefit is not established. |
| Investigated applications | Historical sleep architecture and stress-response hypotheses. | Telomerase, telomere maintenance and pineal-related biology. | Anxiety-related signaling and neurobehavioral hypotheses. |
| Evidence quality | Limited / uncertain | Preclinical | Limited / uncertain |
| What remains uncertain | A historical book chapter is background literature, not modern independently replicated evidence of insomnia treatment. | The linked 2025 study is in human cell lines, including cancer cells—not a human clinical trial or evidence of longer lifespan. | The supplied conference-style citation could not be independently verified. Independent replication and broadly applicable clinical outcome evidence are limited. |
| Safety considerations | FDA identifies inadequate safety information and possible immunogenicity and impurity risks. Effects with sedatives and other neuroactive drugs are insufficiently characterized. | Long-term safety is unknown. Telomere effects in cancer cell lines are not evidence of cancer treatment or safety. FDA identifies immunogenicity and insufficient safety information. | FDA identifies insufficient safety information and possible immunogenicity and impurities. Interactions with psychiatric and sedative medicines are poorly characterized. |
| Regulatory classification | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. |
Comparing molecules is not a recommendation to combine them. Clinical evidence for one product or indication cannot establish another’s safety or effectiveness. Open each profile for study types, source links and important evidence limitations.